Optimizing use of SGLT2 inhibitors and other evidence-based therapies to improve outcomes in patients with type 2 diabetes and chronic kidney disease: An opportunity for pharmacists

被引：6
|
作者：
Neumiller, Joshua J. [1 ]
Shubrook, Jay H. [2 ]
Manley, Tom [3 ]
Alicic, Radica Z. [4 ,5 ,6 ]
Tuttle, Katherine R. [4 ,7 ,8 ]
机构：
[1] Washington State Univ, Coll Pharm & Pharmaceut Sci, Spokane, WA 99202 USA
[2] Touro Univ, Primary Care Dept, Vallejo, CA USA
[3] Natl Kidney Fdn, New York, NY USA
[4] Providence Hlth Care, Providence Med Res Ctr, Spokane, WA USA
[5] Univ Washington, Div Med, Spokane, WA USA
[6] Univ Washington, Div Med, Seattle, WA 98195 USA
[7] Univ Washington, Div Nephrol, Kidney Res Inst, Spokane, WA USA
[8] Univ Washington, Div Nephrol, Kidney Res Inst, Seattle, WA USA
来源：
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY | 2022年 / 79卷 / 01期
关键词：
diabetic kidney disease; kidney outcomes; multidisciplinary care; pharmacist intervention; SGLT2; inhibitor; INTERVENTIONS; MANAGEMENT; MORTALITY; CARE;
D O I：
10.1093/ajhp/zxab271
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
[No abstract available]
引用
收藏
页码：E65 / E70
页数：6
相关论文
共 50 条
  • [21] Network Meta-Analysis on the Effects of SGLT2 Inhibitors Versus Finerenone on Cardiorenal Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease
    Zhao, Li-Min
    Zhan, Ze-Lin
    Ning, Jie
    Qiu, Mei
    FRONTIERS IN PHARMACOLOGY, 2022, 12
  • [22] Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes A Meta-analysis
    McGuire, Darren K.
    Shih, Weichung J.
    Cosentino, Francesco
    Charbonnel, Bernard
    Cherney, David Z. I.
    Dagogo-Jack, Samuel
    Pratley, Richard
    Greenberg, Michelle
    Wang, Shuai
    Huyck, Susan
    Gantz, Ira
    Terra, Steven G.
    Masiukiewicz, Urszula
    Cannon, Christopher P.
    JAMA CARDIOLOGY, 2021, 6 (02) : 148 - 158
  • [23] Evidence-based treatment of hyperglycaemia with incretin therapies in patients with type 2 diabetes and advanced chronic kidney disease
    Tuttle, Katherine R.
    McGill, Janet B.
    DIABETES OBESITY & METABOLISM, 2020, 22 (07): : 1014 - 1023
  • [24] SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases
    Christoph Wanner
    Nikolaus Marx
    Diabetologia, 2018, 61 : 2134 - 2139
  • [25] SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases
    Wanner, Christoph
    Marx, Nikolaus
    DIABETOLOGIA, 2018, 61 (10) : 2134 - 2139
  • [26] Predictors of cardio-kidney complications and treatment failure in patients with chronic kidney disease and type 2 diabetes treated with SGLT2 inhibitors
    Kovesdy, Csaba
    Schmedt, Niklas
    Folkerts, Kerstin
    Bowrin, Kevin
    Raad, Hanaya
    Batech, Michael
    Fried, Linda
    BMC MEDICINE, 2022, 20 (01)
  • [27] Predictors of cardio-kidney complications and treatment failure in patients with chronic kidney disease and type 2 diabetes treated with SGLT2 inhibitors
    Csaba Kovesdy
    Niklas Schmedt
    Kerstin Folkerts
    Kevin Bowrin
    Hanaya Raad
    Michael Batech
    Linda Fried
    BMC Medicine, 20
  • [28] Pharmacokinetic/Pharmacodynamic Properties and Clinical Use of SGLT2 Inhibitors in Non-Asian and Asian Patients with Type 2 Diabetes and Chronic Kidney Disease
    Scheen, Andre J.
    CLINICAL PHARMACOKINETICS, 2020, 59 (08) : 981 - 994
  • [29] Pharmacokinetic/Pharmacodynamic Properties and Clinical Use of SGLT2 Inhibitors in Non-Asian and Asian Patients with Type 2 Diabetes and Chronic Kidney Disease
    André J. Scheen
    Clinical Pharmacokinetics, 2020, 59 : 981 - 994
  • [30] Use of SGLT2 Inhibitors in Patients With Type 2 Diabetes and Chronic Kidney Disease-A Multi-Country Report from the FOUNTAIN Platform
    Johannes, Catherine B.
    Ziemiecki, Ryan
    Pladevall-Vila, Manel
    Kosvesdy, Csaba P.
    Ebert, Natalie
    Thomsen, Reimar W. W.
    Christiansen, Christian Fynbo
    Baak, Brenda
    Robles Cabaninas, Celia
    Kashihara, Naoki
    Yano, Yuichiro
    Kanegae, Hiroshi
    Coleman, Craig I.
    Okami, Suguru
    Liu, Fangfang
    Layton, J. Bradley
    Vizcaya, David
    Oberprieler, Nikolaus G.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 237 - 238
12345